Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.

Autor: Liu KX; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Shaaban SG; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD, USA., Chen JJ; Department of Radiation Oncology, University of California at San Francisco, UCSF Benioff Children's Hospital, San Francisco, CA, USA; Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Bagatell R; Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Lerman BJ; Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pediatrics, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA, USA., Catalano PJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., DuBois SG; Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Shusterman S; Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Ioakeim-Ioannidou M; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Yock TI; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Shamberger RC; Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Mattei P; Department of Surgery, University of Pennsylvania and the Children's Hospital of Philadelphia, Philadelphia, PA, USA., Vu L; Department of Surgery, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA, USA., Elhalawani H; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Dusenbery KE; Department of Radiation Oncology, University of Minnesota, Minneapolis, MN, USA., Vo KT; Department of Pediatrics, UCSF Benioff Children's Hospital and UCSF School of Medicine, San Francisco, CA, USA., Huang MS; Department of Pediatric Oncology, Massachusetts General Hospital, Boston, MA, USA., Friedmann AM; Department of Pediatric Oncology, Massachusetts General Hospital, Boston, MA, USA., Diller LR; Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Marcus KJ; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., MacDonald SM; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Terezakis SA; Department of Radiation Oncology, University of Minnesota, Minneapolis, MN, USA., Braunstein SE; Department of Radiation Oncology, University of California at San Francisco, UCSF Benioff Children's Hospital, San Francisco, CA, USA., Hill-Kayser CE; Department of Radiation Oncology, University of Pennsylvania and the Children's Hospital of Philadelphia, Philadelphia, PA, USA., Haas-Kogan DA; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: dhaas-kogan@bwh.harvard.edu.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Sep; Vol. 198, pp. 110384. Date of Electronic Publication: 2024 Jun 15.

Recognition and Management of the Long-term Effects of Cranial Radiation.

Autor: Shaaban SG; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins Medicine, 401 North Broadway, Suite 1440, Baltimore, MD, 21287, USA., LeCompte MC; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins Medicine, 401 North Broadway, Suite 1440, Baltimore, MD, 21287, USA., Kleinberg LR; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins Medicine, 401 North Broadway, Suite 1440, Baltimore, MD, 21287, USA., Redmond KJ; Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins Medicine, 401 North Broadway, Suite 1440, Baltimore, MD, 21287, USA., Page BR; Department of Radiation Oncology-National Capitol Region, Johns Hopkins Medicine, 6420 Rockledge Drive Suite 1200, Bethesda, MD, 20817, USA. Bpage5@jhmi.edu.

Publikováno v: Current treatment options in oncology [Curr Treat Options Oncol] 2023 Jul; Vol. 24 (7), pp. 880-891. Date of Electronic Publication: 2023 May 05.

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.

Autor: Welsh JW; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jwelsh@mdanderson.org., Tang C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., de Groot P; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hess KR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heymach JV; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Papadimitrakopoulou VA; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cushman TR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chang JY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Simon GR; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ramapriyan R; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barsoumian HB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Menon H; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cortez MA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Massarelli E; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nguyen Q; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sharma P; Department of Genitouirinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Verma V; Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania., Raju U; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shaaban SG; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dadu R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cabanillas ME; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang K; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Anderson C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gomez DR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hahn S; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Komaki R; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2019 Dec; Vol. 7 (12), pp. 1903-1909. Date of Electronic Publication: 2019 Oct 28.

Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States.

Autor: Shaaban SG; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX., Verma V; Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE., Choi JI; Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD., Shabason J; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA., Sharma S; Department of Radiation Oncology, The Mount Sinai Hospital, New York, NY., Glass E; California Protons Cancer Therapy Center, San Diego, CA., Grover S; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA., Badiyan SN; California Protons Cancer Therapy Center, San Diego, CA., Simone CB 2nd; California Protons Cancer Therapy Center, San Diego, CA. Electronic address: charlessimone@umm.edu.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2018 Sep; Vol. 19 (5), pp. e685-e692. Date of Electronic Publication: 2018 May 05.

Testicular Dose During Prophylaxis of Heterotopic Ossification with Radiation Therapy.

Autor: Mourad WF; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, U.S.A. Waleed246@gmail.com.; Department of Radiation Oncology, Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, U.S.A., Ma JK; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, U.S.A., Packianathan S; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, U.S.A., Yan W; Department of Radiation Oncology, University of South Alabama, Mobile, AL, U.S.A., Shaaban SG; Department of Radiation Oncology, Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, U.S.A., Marchan EM; Department of Radiation Oncology, Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, U.S.A., Abdallah LE; Department of Radiation Oncology, Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, U.S.A., He R; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, U.S.A., Mobit PN; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, U.S.A., Yang CC; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, U.S.A., Vijayakumar S; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, U.S.A.

Publikováno v: In vivo (Athens, Greece) [In Vivo] 2017 May-Jun; Vol. 31 (3), pp. 461-466.